Exscientia price target lowered to $10 from $12 at Barclays

Barclays lowered the firm’s price target on Exscientia to $10 from $12 and keeps an Overweight rating on the shares. The analyst believes ESMO abstracts “helps de-risk” preclinical MALT1 and LSD1 inhibitors. With Exscientia’s pipeline re-prioritization, the firm removed adenosine from the model.